Background Estrogen receptor （ER）-negative breast cancer cells are more aggressive than ER-positive cells. Elevated levels of cyclooxygenase-2 （COX-2） and vascular endothelial growth factor-C （VEGF-C） expression...Background Estrogen receptor （ER）-negative breast cancer cells are more aggressive than ER-positive cells. Elevated levels of cyclooxygenase-2 （COX-2） and vascular endothelial growth factor-C （VEGF-C） expression have been detected in cultured human breast cancer cells and are associated with negative hormone receptor status. In this study, we created ERα stable transfectants in MDA-MB-231 cells to explore the effect of ERα on cell growth and COX-2 and VEGF-C expression.Methods The green fluorescent protein （GFP）-ERα plasmids were stably transfected into ER-negative MDA-MB-231 cells. The proliferation and migration of untransfected MDA-MB-231 cells, ERα-transfected MDA-MB-231 cells and ER-positive MCF-7 cells were determined. The expression of COX-2, and the levels of VEGF-C mRNA and the VEGF-C secretion concentration were assayed in these cell lines.Results The proliferation and migration capacities of ERα-tranfected MDA-MB-231 cells were significantly decreased （P 〈0.05）. The expression of COX-2 was significantly lower in ERa-tranfected MDA-MB-231 cells than in untranfected MDA-MB-231 cells. The mRNA and protein levels of VEGF-C were lower in ERa-tranfected MDA-MB-231 cells than in untransfected MDA-MB-231 cells （P〈0.05）.Conclusions ERα stable transfection inhibits proliferation and migration capacities of MDA-MB-231 cells and decreases expression of COX-2 and VEGF-C. The decreases of proliferation and migration capacities may be related to suppression of COX-2 and VEGF-C expression.展开更多
男性乳腺癌(male breast cancer,MBC)是一种少见的恶性疾病,有关治疗及预后的大型临床研究较少,目前对其多依据女性乳腺癌(female breast cancer,FBC)治疗。尽管男性乳腺癌与女性乳腺癌有较多相似之处,但二者仍存在较大差异,主要表现在...男性乳腺癌(male breast cancer,MBC)是一种少见的恶性疾病,有关治疗及预后的大型临床研究较少,目前对其多依据女性乳腺癌(female breast cancer,FBC)治疗。尽管男性乳腺癌与女性乳腺癌有较多相似之处,但二者仍存在较大差异,主要表现在对激素的依赖性及对激素治疗的敏感性不同。男性乳腺癌内分泌治疗的用药选择及用药时机仍存在较多争议,对常规内分泌药物耐药的男性乳腺癌患者的其他安全有效的治疗措施有待进一步研究。本文将就近年来男性乳腺癌药物治疗方面的研究进展进行综述,为临床治疗提供参考。展开更多
基金This work was supported by a grant from the National Natural Science Foundation of China （No. 30600588）.
文摘Background Estrogen receptor （ER）-negative breast cancer cells are more aggressive than ER-positive cells. Elevated levels of cyclooxygenase-2 （COX-2） and vascular endothelial growth factor-C （VEGF-C） expression have been detected in cultured human breast cancer cells and are associated with negative hormone receptor status. In this study, we created ERα stable transfectants in MDA-MB-231 cells to explore the effect of ERα on cell growth and COX-2 and VEGF-C expression.Methods The green fluorescent protein （GFP）-ERα plasmids were stably transfected into ER-negative MDA-MB-231 cells. The proliferation and migration of untransfected MDA-MB-231 cells, ERα-transfected MDA-MB-231 cells and ER-positive MCF-7 cells were determined. The expression of COX-2, and the levels of VEGF-C mRNA and the VEGF-C secretion concentration were assayed in these cell lines.Results The proliferation and migration capacities of ERα-tranfected MDA-MB-231 cells were significantly decreased （P 〈0.05）. The expression of COX-2 was significantly lower in ERa-tranfected MDA-MB-231 cells than in untranfected MDA-MB-231 cells. The mRNA and protein levels of VEGF-C were lower in ERa-tranfected MDA-MB-231 cells than in untransfected MDA-MB-231 cells （P〈0.05）.Conclusions ERα stable transfection inhibits proliferation and migration capacities of MDA-MB-231 cells and decreases expression of COX-2 and VEGF-C. The decreases of proliferation and migration capacities may be related to suppression of COX-2 and VEGF-C expression.
文摘男性乳腺癌(male breast cancer,MBC)是一种少见的恶性疾病,有关治疗及预后的大型临床研究较少,目前对其多依据女性乳腺癌(female breast cancer,FBC)治疗。尽管男性乳腺癌与女性乳腺癌有较多相似之处,但二者仍存在较大差异,主要表现在对激素的依赖性及对激素治疗的敏感性不同。男性乳腺癌内分泌治疗的用药选择及用药时机仍存在较多争议,对常规内分泌药物耐药的男性乳腺癌患者的其他安全有效的治疗措施有待进一步研究。本文将就近年来男性乳腺癌药物治疗方面的研究进展进行综述,为临床治疗提供参考。
